Boston Scientific (BSX) Q1 FY25 earnings call

Boston Scientific delivered a strong Q1 FY25, significantly exceeding revenue and EPS guidance, driven by broad-based cardiology strength and global execution. The company raised its full-year outlook, demonstrating resilience by fully offsetting an unexpected $200 million tariff headwind through increased sales and cost efficiencies. Strategic investments in innovation and acquisitions continue to fuel long-term growth, despite some segment-specific supply chain challenges.